Clearance pathways and what renal impairment changes

Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did.

What changes if the standard account of clearance pathways is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.

Working through the consequences rather than the evidence, since others here are better placed on the evidence.

A request rather than an answer: could whoever has the primary source for clearance pathways post it? I have seen the claim three times this month and each version had lost a qualifier.

Everything in the opening post holds. The case it does not cover is the one I have.

Renal impairment changes clearance for some compounds in this class and not others, and the published data is compound-specific rather than class-wide.

Nothing above should be read as advice about what anyone else should do.

Narrowing the opening post, because the general version has more than one answer.

Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.

That is all I can say without guessing.

Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments might be needed.

Useful. I had the fact and not the reason, which turns out to be the important half.

Answering the question post #5 raises rather than the one it answers.

Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.

I am confident about the direction and much less about the magnitude.

The useful distinction on clearance pathways is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.

Moving an injection by a day changes the concentration-time profile very little at these half-lives. It can change when somebody notices symptoms, which is a different and real thing.

That is the honest state of it as of this week.

Confirming post #9 from a second method, which matters more than confirming it from a second person.

Before the thread moves on from clearance pathways — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

Adding what did not work for me on clearance pathways, since the failures never get written up and they are half the useful information.

Coming back to post #8, because the follow-up matters more than the original answer.

Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number.

Happy to be corrected if someone holds better data than mine.

My understanding of clearance pathways is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.

Hepatic metabolism: the degree to which each compound is hepatically metabolised versus renally cleared is known but varies. Severe liver disease changes clearance.